Development and optimization of nanoestrutured systems intend to nasal administration

• Grant number: 17/06201-9
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: July 01, 2017
• End date: June 30, 2018
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Principal Investigator: Maria Palmira Daflon Gremião
• Grantee: Cintia Marchi
• Host Institution: Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil

Abstract

The blood-brain barrier (BBB) is one of the most important physical barriers in the body that prevents the central nervous system (CSN) from exogenous materials. Although it has a protective function, hinders the passage of some drugs destined to brain tumors treatment. Some alternatives are addressed in an attempt to circumvent this barrier, allowing the drugs to reach their site of action in necessary concentrations to obtain their therapeutic effect. Among them, the use of the nasal route of administration seems to comprise a direct connection between the external environment and the CNS. In addition, drug administrated by this route, is not subject to passage through the BBB. According to the inherent limitations existing at the nasal cavity as enzymatic environment and the occurrence of mucociliary clearance, technological tools can provided pharmacological improvements. The development of polymeric delivery systems might provide drug compartmentalization and vectorization, and, depending on the nature of these polymers, the establishment of interactions with the nasal mucosa, increasing formulation residence time at the nasal cavity. Chitosan and alginate are natural and biocompatible polymers that can be used for this purpose. In this sense, the objective of this work is the use of factorial design and statistical tools to develop mucoadhesive polymeric nanoparticles composed by alginate and chitosan for the administration of alpha-cyano-4 hydroxycinnamic acid (CHC), able to act as a therapeutic agent against tumoral cells. (AU)